Aperio Group LLC Sells 5,057 Shares of The Medicines Company (MDCO)
Aperio Group LLC cut its position in shares of The Medicines Company (NASDAQ:MDCO) by 17.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 23,916 shares of the company’s stock after selling 5,057 shares during the quarter. Aperio Group LLC’s holdings in The Medicines were worth $886,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently modified their holdings of MDCO. PNC Financial Services Group Inc. grew its holdings in shares of The Medicines by 341.2% during the first quarter. PNC Financial Services Group Inc. now owns 2,109 shares of the company’s stock worth $104,000 after buying an additional 1,631 shares in the last quarter. Louisiana State Employees Retirement System grew its holdings in shares of The Medicines by 1.0% during the second quarter. Louisiana State Employees Retirement System now owns 29,400 shares of the company’s stock worth $1,117,000 after buying an additional 300 shares in the last quarter. Parametrica Management Ltd purchased a new stake in shares of The Medicines during the second quarter worth about $268,000. Campbell & CO Investment Adviser LLC purchased a new stake in shares of The Medicines during the second quarter worth about $511,000. Finally, Municipal Employees Retirement System of Michigan grew its holdings in shares of The Medicines by 7.6% during the second quarter. Municipal Employees Retirement System of Michigan now owns 17,050 shares of the company’s stock worth $648,000 after buying an additional 1,200 shares in the last quarter.
A number of equities research analysts have recently commented on the stock. Zacks Investment Research upgraded shares of The Medicines from a “hold” rating to a “buy” rating and set a $41.00 price target for the company in a report on Tuesday, August 8th. Chardan Capital reissued a “buy” rating and issued a $85.00 target price on shares of The Medicines in a research report on Wednesday, September 20th. Guggenheim began coverage on shares of The Medicines in a research report on Monday, October 23rd. They issued a “buy” rating and a $45.00 target price on the stock. Jefferies Group LLC reissued a “buy” rating and issued a $54.00 target price on shares of The Medicines in a research report on Thursday, October 26th. Finally, Oppenheimer Holdings, Inc. set a $50.00 target price on shares of The Medicines and gave the stock a “hold” rating in a research report on Thursday, August 17th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company’s stock. The Medicines has an average rating of “Hold” and a consensus target price of $53.67.
The Medicines Company (NASDAQ MDCO) opened at $31.20 on Tuesday. The company has a quick ratio of 1.79, a current ratio of 2.31 and a debt-to-equity ratio of 3.42. The Medicines Company has a 12-month low of $28.00 and a 12-month high of $55.95.
The Medicines (NASDAQ:MDCO) last announced its quarterly earnings results on Wednesday, October 25th. The company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.95. The firm had revenue of $16.87 million for the quarter, compared to analysts’ expectations of $26.06 million. The Medicines had a negative net margin of 767.94% and a negative return on equity of 174.68%. The Medicines’s revenue was down 55.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.64) earnings per share. equities analysts forecast that The Medicines Company will post -8.84 earnings per share for the current year.
The Medicines Company Profile
The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).
Receive News & Ratings for The Medicines Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines Company and related companies with Analyst Ratings Network's FREE daily email newsletter.